This analysis predicts improved dosing for HIV prevention in women, suggesting effective on-demand regimens.
Using an established pharmacokinetic/pharmacodynamic tissue model of tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis (PrEP), we predict that adding a fourth day of dosing to the 3-day IPERGAY on-demand PrEP regimen (currently approved for men/transgender women who have sex with men) will be efficacious for on-demand dosing in cisgender women.
No takes yet. Share an insight, caveat, or question.
Engel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: